Neuland Laboratories Ltd Share Price – NSE  / BSE

Pharmaceuticals, Small Cap

On a quarter-on-quarter (QoQ) basis, the company's net profit zoomed 596.76%, while revenue rose 75.67% in Q2 FY26. Profit before tax (PBT) soared 161.92% YoY and 636.71% QoQ to Rs 636.71 crore in Q2 FY26.

During the quarter, EBITDA stood at Rs 156.9 crore, registering growth of 138.80% compared with Rs 65.7 crore posted in the same quarter last year. EBITDA margin improved 960 bps to 30.40% in Q2 FY26 as against 20.80% in Q2 FY25.

Total expenses jumped 45.59% to Rs 386.64 crore in Q2 FY26, compared with Rs 265.75 crore in Q2 FY25. The cost of material consumed stood at Rs 227.64 crore (up 70.94% YoY), employee benefit expenses were at Rs 80.37 crore (up 28.43% YoY), finance cost stood at Rs 5.17 crore (up 387.74% YoY), while manufacturing expenses stood at Rs 45.96 crore (up 8.68% YoY) during the period under review.

Sucheth Davuluri, vice-chairman and chief executive officer of the company, said, ?The record high revenue this quarter driven by CMS commercial projects led to the operating leverage reflected in the EBITDA margins, and we expect this momentum to continue through the rest of the year. Given the investments we are making, Neuland is well positioned to take advantage of the number of growth opportunities available to us in both the CDMO and the generic APIs space.

Customer interest in Neuland?s capabilities continues to be on the rise as we see increased engagement with a diverse range of customers. Our reputation and track record as an agile partner is enabling not just new business but also a greater share of business from existing customers. Our investments are going according to plan and helping to further differentiate Neuland as a partner of choice.?

Neuland Laboratories is a pharmaceutical manufacturer providing active pharmaceutical ingredients (APIs), complex intermediates, and custom manufacturing solutions to customers in approximately 80 countries.

Powered by Capital Market - Live News

Net profit of Neuland Laboratories rose 194.91% to Rs 96.85 crore in the quarter ended September 2025 as against Rs 32.84 crore during the previous quarter ended September 2024. Sales rose 65.45% to Rs 514.27 crore in the quarter ended September 2025 as against Rs 310.84 crore during the previous quarter ended September 2024.

Powered by Capital Market - Live News

India Cements Ltd, Five-Star Business Finance Ltd, Sagility Ltd, Endurance Technologies Ltd are among the other stocks to see a surge in volumes on BSE today, 30 October 2025.

Neuland Laboratories Ltd registered volume of 20530 shares by 10:47 IST on BSE, a 16.61 fold spurt over two-week average daily volume of 1236 shares. The stock rose 2.40% to Rs.15,743.55. Volumes stood at 1163 shares in the last session.

India Cements Ltd registered volume of 88566 shares by 10:47 IST on BSE, a 9.86 fold spurt over two-week average daily volume of 8985 shares. The stock rose 5.10% to Rs.411.00. Volumes stood at 13842 shares in the last session.

Five-Star Business Finance Ltd notched up volume of 20.84 lakh shares by 10:47 IST on BSE, a 9.85 fold spurt over two-week average daily volume of 2.12 lakh shares. The stock rose 8.14% to Rs.652.50. Volumes stood at 14.42 lakh shares in the last session.

Sagility Ltd registered volume of 223.05 lakh shares by 10:47 IST on BSE, a 8.89 fold spurt over two-week average daily volume of 25.10 lakh shares. The stock rose 9.96% to Rs.55.98. Volumes stood at 57.99 lakh shares in the last session.

Endurance Technologies Ltd notched up volume of 31455 shares by 10:47 IST on BSE, a 6.32 fold spurt over two-week average daily volume of 4978 shares. The stock rose 0.21% to Rs.2,850.90. Volumes stood at 13535 shares in the last session.

Powered by Capital Market - Live News

Neuland Laboratories will hold a meeting of the Board of Directors of the Company on 7 November 2025.

Powered by Capital Market - Live News